Diagnostic value of CSF biomarker profile in frontotemporal lobar degeneration

Kapaki, E; Paraskevas, GP; Papageorgiou, SG; Bonakis, A; Kalfakis, N; Zalonis, I; Vassilopoulos, D

dc.contributor.author	Kapaki, E	en
dc.contributor.author	Paraskevas, GP	en
dc.contributor.author	Papageorgiou, SG	en
dc.contributor.author	Bonakis, A	en
dc.contributor.author	Kalfakis, N	en
dc.contributor.author	Zalonis, I	en
dc.contributor.author	Vassilopoulos, D	en
dc.date.accessioned	2014-03-01T01:57:24Z
dc.date.available	2014-03-01T01:57:24Z
dc.date.issued	2008	en
dc.identifier.issn	0893-0341	en
dc.identifier.uri	https://dspace.lib.ntua.gr/xmlui/handle/123456789/28409
dc.subject	frontotemporal lobar degeneration	en
dc.subject	Alzheimer disease	en
dc.subject	tau protein	en
dc.subject	phospho-tau	en
dc.subject	beta-amyloid	en
dc.subject.classification	Clinical Neurology	en
dc.subject.classification	Pathology	en
dc.subject.other	CEREBROSPINAL-FLUID TAU	en
dc.subject.other	BETA-AMYLOID 1-42	en
dc.subject.other	NORMAL-PRESSURE HYDROCEPHALUS	en
dc.subject.other	PRIMARY PROGRESSIVE APHASIA	en
dc.subject.other	ALZHEIMERS-DISEASE	en
dc.subject.other	DEMENTIA	en
dc.subject.other	PROTEIN	en
dc.subject.other	DISCRIMINATION	en
dc.subject.other	BETA-AMYLOID(1-42)	en
dc.subject.other	DISORDERS	en
dc.title	Diagnostic value of CSF biomarker profile in frontotemporal lobar degeneration	en
heal.type	journalArticle	en
heal.language	English	en
heal.publicationDate	2008	en
heal.abstract	Background: Cerebrospinal fluid (CSF) biomarkers have been increasingly studied in dementia clinical and differential diagnosis. Methods: We assessed levels of total tau protein (UT), tau phosphorylated at threonine 181 (tau(P-181)), and beta-amytoid(1-42) (A beta 42) in 34 patients with frontotemporal lobar degeneration (FTLD), 76 Alzheimer disease (AD) cases, and 93 controls (CTRL). Double sandwich enzyme-linked immunosorbent assays (Innogenetics) were used for measurements. Results: Total tau was significantly increased and A beta 42 decreased in FTLD and AD patients as compared with CTRL. CSF tau(P-181) levels were significantly increased only in AD. The tau(T)/A beta 42 ratio successfully discriminated FTLD from CTRL with a 86.7% specificity and 80.6% sensitivity, whereas the tau(T) alone was more specific (95.7%) but less sensitive (64.75%). For the discrimination of FTLD from AD, tau(T)/A beta 42 ratio was better (90.3% sensitivity and 64.5% specificity) compared with the other biomarkers alone or in combination, whereas tau(P-181) was less sensitive but more specific (68.4% and 85.7%, respectively). Subtype analysis revealed that the most AD-like profile of biomarkers were observed in FTLD with motor neuron signs, whereas the most non-AD profile were observed in patients with primary progressive aphasia. Conclusions: Combined analysis of CSF biomarkers may be useful for the best possible antemortem discrimination of FTLD from AD.	en
heal.publisher	LIPPINCOTT WILLIAMS & WILKINS	en
heal.journalName	ALZHEIMER DISEASE & ASSOCIATED DISORDERS	en
dc.identifier.isi	ISI:000253700000007	en
dc.identifier.volume	22	en
dc.identifier.issue	1	en
dc.identifier.spage	47	en
dc.identifier.epage	53	en